EICHORCondition: Thyroid Eye Disease · Sponsor: Viridian Therapeutics, Inc.
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Scottsdale Clinical Trials | Scottsdale, Arizona, United States | — |
| Alliance Research Institute - Canoga Park | Canoga Park, California, United States | — |
| Marvel Clinical Research | Huntington Beach, California, United States | — |
| United Medical Research Institute | Inglewood, California, United States | — |
| Advancing Research International, LLC | Los Angeles, California, United States | — |
| Roski Eye Institute, Keck School of Medicine, USC | Los Angeles, California, United States | — |
| Alliance Research Institute - Lynwood | Lynwood, California, United States | — |
| A.P.J. Office | Newport Beach, California, United States | — |
| Byers Eye Institute at Stanford University | Palo Alto, California, United States | — |
| Pasadena Clinical Trials | Pasadena, California, United States | — |
| Senta Clinic | San Diego, California, United States | — |
| C&A Clinical Trials Corp | Cape Coral, Florida, United States | — |
+ 22 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06625411